Intellia Therapeutics (NTLA) — Entry Risk Score
Stock · re-scored every trading day · data as of 2026-11-12
The entry score measures one thing: how far Intellia Therapeutics's price sits from a defensible technical level, on a 30–98 scale. High scores (79+) mean the price has pulled back into a zone where risk can be defined; low scores mean the price is extended above its own trend — not that the stock is bad, but that chasing it here carries undefined risk. The full formula is public on our methodology page.
On 2026-11-12, Intellia Therapeutics's price sits 1.41 ATR below its 20-day average ($11.75); it trades below its 200-day average ($12.98); its 14-day RSI is 40; it has moved -7.62% over 20 sessions; our regime filter classifies it as no confirmed trend.
Falling-knife flag: this Buy Zone score comes on top of a -15.19% decline over roughly 60 sessions. In our own data that pattern has swung harder than other Buy Zone names in both directions. See the audit.
Is Intellia Therapeutics (NTLA) a buy right now?
Intellia Therapeutics scores 84/98 (Buy) as of 2026-11-12; it is 40.9% below its 52-week high of $17.84; it is below its 200-day average; it moved -7.05% over the last 5 sessions. A high score means our model rates today's price as a favorable, defined-risk entry, based on where it sits versus its 20-day average after adjusting for trend and volatility. It is not a prediction that the price will rise. It also carries a falling-knife flag (down 15.19% over ~60 sessions). Not investment advice.
Score history
Every point is a recorded daily snapshot, committed publicly the evening it was scored — history can't be rewritten after the fact.
| Date | Score | Δ | Close |
|---|---|---|---|
| 2026-11-12 | 84 | +3 | $10.55 |
| 2026-11-06 | 81 | -3 | $11.35 |
| 2026-11-05 | 84 | +10 | $11.10 |
| 2026-11-04 | 74 | -4 | $12.31 |
| 2026-11-03 | 78 | -4 | $11.86 |
| 2026-11-02 | 82 | +9 | $11.66 |
| 2026-10-29 | 73 | +2 | $13.23 |
| 2026-10-28 | 71 | -3 | $13.32 |
| 2026-10-27 | 74 | -9 | $12.28 |
| 2026-10-26 | 83 | -1 | $11.26 |
| 2026-10-23 | 84 | -2 | $11.21 |
| 2026-10-22 | 86 | +4 | $11.16 |
Related stocks
See today's full rankings + entry plan for NTLA →Get the Sunday Brief
One email a week, before the open: what the board did, which calls worked, which didn't, and what changed. Free. No spam, unsubscribe anytime.